Repligen Corporation (RGEN) to Post FY2020 Earnings of $1.12 Per Share, Jefferies Group Forecasts
Repligen Corporation (NASDAQ:RGEN) – Equities researchers at Jefferies Group issued their FY2020 earnings per share (EPS) estimates for shares of Repligen Corporation in a research report issued to clients and investors on Tuesday. Jefferies Group analyst B. Couillard forecasts that the biotechnology company will post earnings of $1.12 per share for the year. Jefferies Group has a “Hold” rating and a $40.00 price objective on the stock.
Repligen Corporation (NASDAQ:RGEN) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. Repligen Corporation’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period last year, the company earned $0.16 earnings per share.
ILLEGAL ACTIVITY WARNING: “Repligen Corporation (RGEN) to Post FY2020 Earnings of $1.12 Per Share, Jefferies Group Forecasts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/04/repligen-corporation-rgen-to-post-fy2020-earnings-of-1-12-per-share-jefferies-group-forecasts.html.
A number of other brokerages have also recently commented on RGEN. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Saturday, August 12th. TheStreet raised Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. First Analysis raised Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 price target on the stock in a report on Monday. Finally, Stephens restated an “overweight” rating and issued a $50.00 price target on shares of Repligen Corporation in a research report on Tuesday, September 26th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $46.00.
Shares of Repligen Corporation (RGEN) traded up 0.50% on Wednesday, reaching $38.27. The company had a trading volume of 201,400 shares. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81. The company’s 50-day moving average price is $41.87 and its 200 day moving average price is $39.55. The firm has a market capitalization of $1.43 billion, a P/E ratio of 74.89 and a beta of 1.18.
Large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. purchased a new position in Repligen Corporation in the 1st quarter valued at $103,000. Victory Capital Management Inc. increased its stake in Repligen Corporation by 76.6% in the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares during the period. Quantbot Technologies LP purchased a new position in Repligen Corporation during the 2nd quarter worth $120,000. Oppenheimer Asset Management Inc. purchased a new position in Repligen Corporation during the 2nd quarter worth $123,000. Finally, JPMorgan Chase & Co. raised its position in Repligen Corporation by 31.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after buying an additional 908 shares during the last quarter. Hedge funds and other institutional investors own 97.91% of the company’s stock.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.